Initiator Pharma A/S OMXSTO:INIT:
Q1 2026 NET REVENUE WAS KDKK 0
Q1 2026 OPERATING LOSS, EBIT WAS KDKK -11,432
Initiator Pharma Q1 2026 Operating Loss DKK 11.4 Mln
Earlier from Initiator Pharma
- Initiator Pharma progresses patient enrollment in Phase 2a vulvodynia study
- Initiator Pharma: Full focus on pudafensine, IP2018 is discontinued
- Initiator Pharma To Fully Prioritize Pudafensine
- Initiator Pharma to present at Redeye Healthcare Day 2026
- INIT: Pudafensine targets major unmet needs in ED and vulvodynia, with pivotal data expected by 2026
Later from Initiator Pharma
- Initiator Pharma A/S calls for the Annual General Meeting
- Initiator Pharma A/S – Resolutions of the annual general meeting 2026
- Initiator Pharma attends BIO 2026 in San Diego
- Initiator Pharma secures two European patents for pudafensine
- Initiator Pharma strengthens its management team – appoints Annette Säfholm as COO
Follow Initiator Pharma into a list and get an email when it puts out news.
Follow Initiator Pharma